Logos Global Management LP Prelude Therapeutics Inc Transaction History

Logos Global Management LP

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q4 2021 Feb 14, 2022	SELL	$11.89 - $31.74 $4.76 Million - $12.7 Million	-400,000 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$28.63 - $44.3 $11.5 Million - $17.7 Million	400,000 New	400,000 $11.5 Million

35.7M

500

300

Ticker PRLD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,369,200
Market Cap $34.6M
Description
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid ...

Get notified when there are updates to the investment portfolio of Logos Global Management LP, based on Form 13F filings with the SEC.

Stay updated on Logos Global Management LP with notifications on news.